CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...

CNTX has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. This experimental ...

JMP Securities initiated coverage of Context Therapeutics (CNTX) with an Outperform rating and $4 price target Context is a $97.8M market cap ...

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive ...

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...

Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...